Optochemical Control of Immune Checkpoint Blockade via Light‐Triggered PD‐L1 Dimerization. Issue 6 (16th May 2022)

• Record Type: Journal Article
• Authors: Liu, Yuwei; Long, Kaiqi; Kang, Weirong; Wang, Tianyi; Wang, Weiping
• Is Part Of: Advanced nanobiomed research. Volume 2:Issue 6(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-05-16
• Subjects: immune checkpoint blockade -- immunotherapy -- PD-L1 dimerization -- photopharmacology -- photoresponsive prodrug; Nanomedicine -- Periodicals; Biomedical engineering -- Periodicals; Biomedical materials -- Periodicals; Nanomedicine; Nanostructures; Bioengineering; Biocompatible Materials; Electronic journals; Periodicals; Periodical; 610.28
• DOI: 10.1002/anbr.202200017
• Languages: English
• ISSNs: 2699-9307

Abstract

Abstract : The blockade of PD‐1/PD‐L1, which serves to "release the brake" of tumor immunity, represents a promising approach for treating various malignancies. However, the systemic immune‐related side effects significantly undermine its therapeutic efficacy. To address this dilemma, a photoactivatable and biocompatible prodrug cBMS‐1 based on the concept of photopharmacology is reported. The prodrug exhibits negligible toxicity but exerts effective PD‐1/PD‐L1 axis inhibition upon light irradiation, holding promising potential to achieve local activation of immune responses in clinical settings. Abstract : A photoactivatable and biocompatible prodrug is developed, which exhibits negligible cytotoxicity but exerts effective PD‐1/PD‐L1 axis inhibition upon light irradiation. The light‐triggered immune checkpoint blockade controls biological functions of immune cells in a precisely controlled way.